Acadia Pharmaceuticals Inc

+0.80 (+5.12%)

Acadia Pharmaceuticals Says Receives CRL From U.S. FDA For Supplemental New Drug Application For Pimavanserin

Published: 08/05/2022 03:17 GMT
Acadia Pharmaceuticals Inc (ACAD) - Acadia Pharmaceuticals Receives Complete Response Letter From U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Alzheimer’s Disease Psychosis.
Crl Indicated FDA Completed Review of Application, Determining That It Could Not Approve Snda in Its Present Form.
FDA Recommended That Acadia Conduct an Additional Trial in Adp.
FDA Concluded That There Are Limitations in Interpretability of 019 Results.